Trials / Recruiting
RecruitingNCT06671496
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zasocitinib | Zasocitinib tablets. |
| DRUG | Placebo | Zasocitinib matching placebo. |
Timeline
- Start date
- 2025-03-10
- Primary completion
- 2027-05-18
- Completion
- 2028-01-26
- First posted
- 2024-11-04
- Last updated
- 2026-04-06
Locations
122 sites across 12 countries: United States, Argentina, Australia, Brazil, Canada, China, France, Germany, Japan, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06671496. Inclusion in this directory is not an endorsement.